# Aura Biosciences, Inc. (AURA)

> Source: Nexqual · https://nexqual.com/AURA · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Aura Biosciences, Inc. (AURA), nexqual.com/AURA" · informational, not investment advice.

**Price:** USD 6.3 (-1.64% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 6.4 · day 6.26–6.51 · 52w 4.73–9.54 · market cap $653M · NGM

## Key facts
- Analysts: Buy (mean 1.83 on a 1–5 scale) (6 analysts), mean target USD 16.6 (range 12–23).
- Total return with dividends: 1Y +5.3% vs S&P 500 +14.8%; 5Y -57.5% vs S&P 500 +79.1%.
- Next earnings: 2026-11-12 (date not yet confirmed by the company), EPS estimate USD -0.37, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-12
- Dividend: AURA paid no cash dividend in the last five years.
- Short interest: 10.57% of float (as of 2026-10-15), 10.2 days to cover.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 2.1x · FCF yield -15.57% · Earnings yield -19.74%

## Analysts
Consensus Buy (mean 1.83 on a 1–5 scale), 6 analysts; mean target USD 16.6 (low 12, high 23).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-11 | HC Wainwright & Co. | Target lowered | Buy | $24 → $18 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +5.3% | -57.5% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +5.3% | -15.7% |
| Volatility (annualized) | 54.5% | 64.2% |
| Max drawdown | -32.6% (May 2026→Sep 2026) | -77.8% (Nov 2021→Jan 2026) |

## Dividends
AURA paid no cash dividend in the last five years.

## Short interest
10,885,962 shares sold short, 10.57% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 7,049,973 shares (+54.4%). Days to cover: 10.2 (short shares ÷ average daily volume).

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 93.07 +1.20% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/AURA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.37 | $-0.37 | $0.00 | $0 | 4 |
| Next quarter (ends 2026-12-31) | $-0.35 | $-0.38 | +$0.03 | $0 | 4 |
| Current fiscal year (ends 2026-12-31) | $-1.67 | $-1.59 | −$0.07 | $0 | 4 |
| Next fiscal year (ends 2027-12-31) | $-1.52 | $-1.67 | +$0.15 | $4.9M | 4 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.48 | −$0.37 | Miss −29.7% | — |
| — | Quarter ended Mar 31, 2026 | −$0.50 | −$0.40 | Miss −25.0% | — |
| — | Quarter ended Dec 31, 2025 | −$0.37 | −$0.43 | Beat +14.0% | — |
| — | Quarter ended Sep 30, 2025 | −$0.40 | −$0.47 | Beat +14.9% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).